Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.

MLA

Nastoupil, Loretta J., et al. “Phase 3 SELENE Study: Ibrutinib plus BR/R-CHOP in Previously Treated Patients with Follicular or Marginal Zone Lymphoma.” Blood Advances, vol. 7, no. 22, Nov. 2023, pp. 7141–50. EBSCOhost, https://doi.org/10.1182/bloodadvances.2023010298.

APA

Nastoupil, L. J., Hess, G., Pavlovsky, M. A., Danielewicz, I., Freeman, J., García-Sancho, A. M., Glazunova, V., Grigg, A., Hou, J.-Z., Janssens, A., Kim, S. J., Masliak, Z., McKay, P., Merli, F., Munakata, W., Nagai, H., Özcan, M., Preis, M., Wang, T., … Salles, G. (2023). Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Advances, 7(22), 7141–7150. https://doi.org/10.1182/bloodadvances.2023010298

Chicago

Nastoupil, Loretta J, Georg Hess, Miguel A Pavlovsky, Iwona Danielewicz, Jane Freeman, Alejandro Martin García-Sancho, Valeria Glazunova, et al. 2023. “Phase 3 SELENE Study: Ibrutinib plus BR/R-CHOP in Previously Treated Patients with Follicular or Marginal Zone Lymphoma.” Blood Advances 7 (22): 7141–50. doi:10.1182/bloodadvances.2023010298.